Tebentafusp

other

Identifier: CI-DRUG-00000751
Entity page: /drug/tebentafusp ↗
Edges: 29

Neighbours: 5 cancers1 genes18 trials1 approvals
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Tebentafusp approved for …APPROVED_FOR4 of 3
→ approved for	Uveal Melanomasubtype	supports	FDA ORIG	Uveal Melanoma	1	Regulatory	openfda	graph →
→ approved for	Uveal Neoplasmcancer_family	supports	mesh_therapeutic_area

Tebentafusp targets …TARGETS1 of 1
→ targets	PMEL	—	BINDING AGENT	—	1	Curated	chembl	graph →

Tebentafusp targets …TARGETS1 of 1

→ targets

PMEL

—

BINDING AGENT

—

Curated

Tebentafusp investigated for …INVESTIGATED_FOR4 of 4
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Melanomacancer_family	unknown	4	Melanoma	1	Curated	chembl	graph →
→ investigated for	Uveal Neoplasmcancer_family	unknown	4	Uveal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Uveal Melanomasubtype	unknown	3	Uveal Melanoma	1	Curated	chembl	graph →

Tebentafusp investigated in trials for …INVESTIGATED_IN_TRIALSderived3 of 3
→ investigated in trials for	Uveal Melanomasubtype 10 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Uveal Melanoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanomacancer_family 7 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Clear Cell Sarcoma of Soft Tissue 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Clear Cell Sarcoma of Soft Tissue	1	Observed	clinicaltrials	graph →

Tebentafusp studied in …STUDIED_INderived18 of 18show fewer
→ studied in	NCT07057596Phase 2 · recruiting Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma · 18 trials list this drug (11 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06070012Phase 2 · recruiting Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · 18 trials list this drug (11 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06626516Phase 1/Phase 2 · recruiting Tebentafusp-tebn With LDT in Metastatic UM · 18 trials list this drug (11 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06246149Phase 3 · recruiting Adjuvant Tebentafusp in High Risk Ocular Melanoma · 18 trials list this drug (11 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06414590Phase 2 · recruiting Neoadjuvant Tebentafusp for Uveal Melanoma · 18 trials list this drug (11 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07276386Phase 2 · recruiting Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma · 18 trials list this drug (11 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03070392Phase 2 · completed Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma · 18 trials list this drug (11 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05549297Phase 3 · recruiting Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) · 18 trials list this drug (11 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06627244Phase 2 · recruiting Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma · 18 trials list this drug (11 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06942442Phase 2 · recruiting A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma · 18 trials list this drug (11 active)	—	—	Clear Cell Sarcoma of Soft Tissue	1	Observed	clinicaltrials	graph →
→ studied in	NCT05315258Phase 2 · active not recruiting Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma · 18 trials list this drug (11 active)	—	—	Melanoma,Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05785754Phase 1 · recruiting DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors · 18 trials list this drug (11 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT02535078Phase 1/Phase 2 · withdrawn Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma · 18 trials list this drug (11 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02570308Phase 1/Phase 2 · completed A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma · 18 trials list this drug (11 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04960891available A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp · 18 trials list this drug (11 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02889861Phase 2 · terminated IMCgp100-401 Rollover Study · 18 trials list this drug (11 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01211262Phase 1 · completed Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma · 18 trials list this drug (11 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01209676early Phase 1 · completed IMCgp100 in Advanced Unresectable Melanoma · 18 trials list this drug (11 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths